61 related articles for article (PubMed ID: 32289300)
1. Preoperative Chemoradiation Versus Chemotherapy in Gastroesophageal Junction Adenocarcinoma.
Zafar SN; Blum M; Chiang YJ; Ajani JA; Estrella JS; Das P; Minsky BD; Hofstetter WL; Mansfield P; Badgwell BD; Ikoma N
Ann Thorac Surg; 2020 Aug; 110(2):398-405. PubMed ID: 32289300
[TBL] [Abstract][Full Text] [Related]
2. Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery.
Rahman S; Thomas B; Maynard N; Park MH; Wahedally M; Trudgill N; Crosby T; Cromwell DA; Underwood TJ
Br J Surg; 2022 Feb; 109(2):227-236. PubMed ID: 34910129
[TBL] [Abstract][Full Text] [Related]
3. Executive Summary of the American Radium Society Appropriate Use Criteria for Operable Esophageal and Gastroesophageal Junction Adenocarcinoma: Systematic Review and Guidelines.
Anker CJ; Dragovic J; Herman JM; Bianchi NA; Goodman KA; Jones WE; Kennedy TJ; Kumar R; Lee P; Russo S; Sharma N; Small W; Suh WW; Tchelebi LT; Jabbour SK
Int J Radiat Oncol Biol Phys; 2021 Jan; 109(1):186-200. PubMed ID: 32858113
[TBL] [Abstract][Full Text] [Related]
4. Esophagogastric junction adenocarcinoma: Preoperative chemoradiation or perioperative chemotherapy?
Laxague F; Schlottmann F
World J Clin Oncol; 2021 Jul; 12(7):557-564. PubMed ID: 34367928
[TBL] [Abstract][Full Text] [Related]
5. Utilization and survival outcomes of neoadjuvant chemotherapy for early-stage gastric cancer.
Janczewski LM; Buchheit J; Jacobs RC; Vitello D; Wells A; Abad J; Bentrem DJ; Chawla A
J Surg Oncol; 2024 Jun; ():. PubMed ID: 38884323
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in preoperative management of esophageal adenocarcinoma.
Harada K; Mizrak Kaya D; Baba H; Ajani JA
F1000Res; 2017; 6():501. PubMed ID: 28491289
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy for poor pathologic response after pre-operative chemoradiation in esophageal cancer: infeasible and illogical.
Greally M; Ku GY
J Thorac Dis; 2019 Sep; 11(Suppl 15):S1855-S1860. PubMed ID: 31632768
[No Abstract] [Full Text] [Related]
8. Correction: Population Based Time Trends in the Epidemiology and Mortality of Gastroesophageal Junction and Esophageal Adenocarcinoma.
Agarwal S; Bell MG; Dhaliwal L; Codipilly DC; Dierkhising RA; Lansing R; Gibbons EE; Leggett CL; Kisiel JB; Iyer PG
Dig Dis Sci; 2024 Mar; 69(3):1070. PubMed ID: 38261115
[No Abstract] [Full Text] [Related]
9. Comment on "Association of systemic inflammatory markers and tertiary lymphoid structure with pathological complete response in gastric cancer patients receiving preoperative treatment: A retrospective cohort study".
Xie S; Zhi Y; Shao C; Zeng B
Int J Surg; 2024 Mar; ():. PubMed ID: 38518078
[No Abstract] [Full Text] [Related]
10. Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer.
Stark AP; Estrella JS; Chiang YJ; Das P; Minsky BD; Blum Murphy MA; Ajani JA; Mansfield P; Badgwell BD; Ikoma N
J Surg Oncol; 2020 Sep; 122(3):422-432. PubMed ID: 32462681
[TBL] [Abstract][Full Text] [Related]
11. Multi-institutional Evaluation of Curative Intent Chemoradiotherapy for Patients With Clinical T1N0 Esophageal Adenocarcinoma.
Deng W; Jethwa KR; Gonuguntla K; Liao Z; Yoon HH; Murphy MB; Haddock MG; Hallemeier CL; Lin SH
Adv Radiat Oncol; 2020; 5(5):951-958. PubMed ID: 33083658
[TBL] [Abstract][Full Text] [Related]
12. Current status of endoscopic submucosal tunnel dissection for treatment of superficial gastrointestinal neoplastic lesions.
Tan Y; Lu J; Lv L; Le M; Liu D
Expert Rev Gastroenterol Hepatol; 2020 Jun; 14(6):453-462. PubMed ID: 32394748
[TBL] [Abstract][Full Text] [Related]
13. Treatment Patterns for Gastroesophageal Junction Adenocarcinoma in the United States.
Kim BJ; Chiang YJ; Das P; Minsky BD; Blum MA; Ajani JA; Estrella JS; Hofstetter WL; Tzeng CD; Badgwell BD; Mansfield PF; Ikoma N
J Clin Med; 2020 Oct; 9(11):. PubMed ID: 33138060
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcome in Patients with Carcinoma of the Esophagogastric Junction Treated with Neoadjuvant Radiochemotherapy or Perioperative Chemotherapy: A Two-Center Retrospective Analysis.
Wundsam HV; Doleschal B; Prommer R; Venhoda C; Schmitt C; Petzer A; Metz-Gercek S; Rumpold H
Oncology; 2020; 98(10):706-713. PubMed ID: 32516775
[TBL] [Abstract][Full Text] [Related]
15. Low-Dose Radiation Yields Lower Rates of Pathologic Response in Esophageal Cancer Patients.
Mantziari S; Farinha HT; Messier M; Winiker M; Allemann P; Ozsahin EM; Demartines N; Piessen G; Schäfer M
Ann Surg Oncol; 2024 Apr; 31(4):2499-2508. PubMed ID: 38198002
[TBL] [Abstract][Full Text] [Related]
16. Independent Stage Classification for Gastroesophageal Junction Adenocarcinoma.
Hirata Y; Chiang YJ; Estrella JS; Das P; Minsky BD; Blum Murphy M; Ajani JA; Mansfield P; Badgwell BD; Ikoma N
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958312
[TBL] [Abstract][Full Text] [Related]
17. Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for locally advanced gastric cancer: a systematic review and meta-analysis.
Zhu Y; Chen J; Sun X; Lou Y; Fang M; Zhou F; Zhang L; Xin Y
Front Oncol; 2023; 13():1177557. PubMed ID: 37228495
[TBL] [Abstract][Full Text] [Related]
18. Nonoperative management of gastrointestinal malignancies in era of neoadjuvant treatment.
Chen N; A Ajani J; Wu A
Chin J Cancer Res; 2023 Feb; 35(1):44-57. PubMed ID: 36910854
[TBL] [Abstract][Full Text] [Related]
19. Borrmann Type Predicts Response to Preoperative Therapy in Advanced Gastric Cancer.
Hirata Y; Agnes A; Prakash LR; Mansfield P; Badgwell BD; Ikoma N
J Gastrointest Cancer; 2023 Sep; 54(3):882-889. PubMed ID: 36308675
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
